Literature DB >> 24902063

Increased levels of osteopontin in sputum supernatant in patients with COPD.

Anastasia Papaporfyriou1, Stelios Loukides2, Konstantinos Kostikas3, Davina C M Simoes4, Georgios Papatheodorou5, Elissavet Konstantellou1, Georgios Hillas2, Spyros Papiris3, Nikolaos Koulouris1, Petros Bakakos6.   

Abstract

BACKGROUND: Osteopontin (OPN) is a phosphorylated acidic glycoprotein that can function as both an extracellular matrix molecule and a cytokine. Published data support that OPN is upregulated in surgical lung tissue samples of patients with COPD. The aim of this study was to determine the levels of OPN in sputum supernatants of patients with COPD and to investigate possible associations with mediators and cells involved in the inflammatory and remodeling process as well as with the extent of emphysema.
METHODS: Seventy-seven patients with COPD and 40 healthy subjects (20 smokers) were studied. All subjects underwent lung function tests, sputum induction for cell count identification, and OPN, transforming growth factor-β1, matrix metalloproteinase (MMP)-2, IL-8, and leukotriene-4 measurement in sputum supernatants. High-resolution CT (HRCT) scan of the chest was performed for quantification of emphysema.
RESULTS: OPN levels (pg/mL) were significantly higher in patients with COPD compared with healthy smokers and nonsmokers (median [interquartile range], 1,340 [601, 6,227] vs 101 [77, 110] vs 68 [50, 89], respectively; P < .001). Regression analysis showed a significant association between OPN and sputum neutrophils, IL-8, MMP-2, and the extent of emphysema. The associations previously listed were not observed in healthy subjects.
CONCLUSIONS: OPN levels are higher in patients with COPD compared with healthy subjects. OPN may play a role in the neutrophilic inflammation and in the pathogenesis of emphysema.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24902063     DOI: 10.1378/chest.13-2440

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  TGF-β1 Impairs Vitamin D-Induced and Constitutive Airway Epithelial Host Defense Mechanisms.

Authors:  Jasmijn A Schrumpf; Dennis K Ninaber; Anne M van der Does; Pieter S Hiemstra
Journal:  J Innate Immun       Date:  2019-04-10       Impact factor: 7.349

Review 2.  Targeting the alternative oxidase (AOX) for human health and food security, a pharmaceutical and agrochemical target or a rescue mechanism?

Authors:  Marten Szibor; Christina Schenkl; Mario R O Barsottini; Luke Young; Anthony L Moore
Journal:  Biochem J       Date:  2022-06-30       Impact factor: 3.766

3.  Identification of the key genes in chronic obstructive pulmonary disease by weighted gene co-expression network analysis.

Authors:  Zhefan Xie; Tingting Xia; Dongxue Wu; Li Che; Wei Zhang; Xingdong Cai; Shengming Liu
Journal:  Ann Transl Med       Date:  2022-06

4.  Osteopontin protects against lung injury caused by extracellular histones.

Authors:  Gopinath Kasetty; Praveen Papareddy; Ravi K V Bhongir; Mohamad N Ali; Michiko Mori; Malgorzata Wygrecka; Jonas S Erjefält; Anna Hultgårdh-Nilsson; Lena Palmberg; Heiko Herwald; Arne Egesten
Journal:  Mucosal Immunol       Date:  2018-08-16       Impact factor: 7.313

5.  Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism.

Authors:  Kittipong Maneechotesuwan; Kanda Kasetsinsombat; Adisak Wongkajornsilp; Peter J Barnes
Journal:  Respir Res       Date:  2016-08-24

6.  Utility of Plasma Osteopontin Levels in Management of Community-Acquired Pneumonia.

Authors:  Jer-Hwa Chang; Wen-Yueh Hung; Kuan-Jen Bai; Shun-Fa Yang; Ming-Hsien Chien
Journal:  Int J Med Sci       Date:  2016-08-10       Impact factor: 3.738

7.  Roundabout signaling pathway involved in the pathogenesis of COPD by integrative bioinformatics analysis.

Authors:  Yuan-Zhen Lin; Xiao-Ning Zhong; Xin Chen; Yi Liang; Hui Zhang; Dong-Lan Zhu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-09-18

8.  Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Authors:  Vasiliki Petta; Stelios Loukides; Konstantinos Kostikas; Andriana I Papaioannou; Georgios Papatheodorou; Kyriaki Cholidou; Ioannis Tomos; Spyridon Papiris; Nikolaos G Koulouris; Petros Bakakos
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Osteopontin That Is Elevated in the Airways during COPD Impairs the Antibacterial Activity of Common Innate Antibiotics.

Authors:  Anele Gela; Ravi K V Bhongir; Michiko Mori; Paul Keenan; Matthias Mörgelin; Jonas S Erjefält; Heiko Herwald; Arne Egesten; Gopinath Kasetty
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

Review 10.  Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight.

Authors:  Anne-Sophie Lamort; Ioanna Giopanou; Ioannis Psallidas; Georgios T Stathopoulos
Journal:  Cells       Date:  2019-08-02       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.